Rani Therapeutics Valuation
| RANI Stock | USD 1.99 0.04 2.05% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Rani Therapeutics holds a recent Real Value of $7.03 per share. The prevailing price of the company is $1.99. Our model determines the value of Rani Therapeutics from analyzing the company fundamentals such as Shares Owned By Institutions of 19.58 %, return on equity of -2.25, and Shares Outstanding of 33.31 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Rani Therapeutics' valuation include:
Price Book 21.2468 | Enterprise Value 69.6 M | Enterprise Value Ebitda (1.42) | Price Sales 313.1706 | Enterprise Value Revenue 84.2765 |
Undervalued
Today
Please note that Rani Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Rani Therapeutics is based on 3 months time horizon. Increasing Rani Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Rani Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Rani Stock. However, Rani Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.99 | Real 7.03 | Target 22.25 | Hype 1.95 |
The intrinsic value of Rani Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Rani Therapeutics' stock price.
Estimating the potential upside or downside of Rani Therapeutics Holdings helps investors to forecast how Rani stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rani Therapeutics more accurately as focusing exclusively on Rani Therapeutics' fundamentals will not take into account other important factors: When choosing an evaluation method for Rani Therapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Rani Therapeutics Cash |
|
Rani Valuation Trend
Rani Therapeutics' real value analysis enables investors to forecast the earnings more efficiently. Using both Rani Therapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Rani Valuation Data Drivers
Rani Therapeutics Total Value Analysis
Rani Therapeutics Holdings is at this time estimated to have valuation of 69.62 M with market capitalization of 116.52 M, debt of 30.1 M, and cash on hands of 98.17 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Rani Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
69.62 M | 116.52 M | 30.1 M | 98.17 M |
Rani Therapeutics Asset Utilization
One of the ways to look at asset utilization of Rani is to check how much profit was generated for every dollar of assets it reports. Rani Therapeutics holds a negative application of assets of -0.57 pct., losing $0.005683 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Rani Therapeutics Holdings shows how discouraging it operates for each dollar spent on its assets.Rani Therapeutics Ownership Allocation
Rani Therapeutics owns a total of 33.31 Million outstanding shares. Rani Therapeutics has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Rani Therapeutics Profitability Analysis
Net Loss for the year was (33.97 M) with profit before overhead, payroll, taxes, and interest of 2.72 M.About Rani Therapeutics Valuation
An absolute valuation paradigm, as applied to Rani Stock, attempts to find the value of Rani Therapeutics based on its fundamental and basic technical indicators. By analyzing Rani Therapeutics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Rani Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Rani Therapeutics. We calculate exposure to Rani Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Rani Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -822 K | -780.9 K | |
| Pretax Profit Margin | (17.57) | (18.45) | |
| Operating Profit Margin | (17.09) | (17.95) | |
| Net Loss | (17.59) | (18.46) |
Rani Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 25.5 M |
Rani Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Rani Therapeutics Holdings and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Rani we look at many different elements of the entity such as Rani's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Rani Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Rani Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Rani Therapeutics' worth.Complementary Tools for Rani Stock analysis
When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |